{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:26:56Z","timestamp":1783466816194,"version":"3.55.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/14656566.2023.2214677","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T08:42:53Z","timestamp":1684140173000},"page":"1105-1111","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Evaluating everolimus for the treatment of breast cancer"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8483","authenticated-orcid":false,"given":"Camille","family":"Moreau-Bachelard","sequence":"first","affiliation":[{"name":"Medical Oncology, ICO Centre Ren\u00e9 Gauducheau, Oncology, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robert","sequence":"additional","affiliation":[{"name":"Medical Oncology, ICO Centre Ren\u00e9 Gauducheau, Oncology, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Gourmelon","sequence":"additional","affiliation":[{"name":"Medical Oncology, ICO Centre Ren\u00e9 Gauducheau, Oncology, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bourbouloux","sequence":"additional","affiliation":[{"name":"Medical Oncology, ICO Centre Ren\u00e9 Gauducheau, Oncology, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Patsouris","sequence":"additional","affiliation":[{"name":"Medical Oncology, ICO Centre Paul Papin, Oncology, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Frenel","sequence":"additional","affiliation":[{"name":"Medical Oncology, ICO Centre Ren\u00e9 Gauducheau, Oncology, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[{"name":"Medical Oncology, ICO Centre Ren\u00e9 Gauducheau, Oncology, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920940939"},{"key":"cit0003","unstructured":"Targeting the PI3K\/AKT\/mTOR pathway in hormone-positive breast cancer | SpringerLink [Internet]. [cited 2021 Oct 29];Availablefrom: https:\/\/link.springer.com\/article\/10.1007%2Fs40265-020-01394-w"},{"issue":"4","key":"cit0004","first-page":"347","volume":"15","author":"Hartkopf AD","year":"2020","journal-title":"BRC"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.07.007"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0489"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041743"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2630-y"},{"key":"cit0009","unstructured":"Everolimus | 159351-69-6 [Internet]. [cited 2022 Jan 26];Available from: https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB9502411.htm"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.0988"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(01)15633-X"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443020-00002"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.0708"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.09.004"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3428"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9331"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3599-5"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05280-2"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2262"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2114"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2526"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.05.008"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.3331"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00051-0"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70138-X"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8391"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08612-y"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.017"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu124"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3634"},{"key":"cit0032","unstructured":"No Benefit Found for Everolimus Plus Adjuvant Hormone Therapy in High-Risk Early-Stage Breast Cancer - the ASCO Post [Internet]. [cited 2021 Nov 25];Available from: https:\/\/ascopost.com\/issues\/march-25-2021\/no-benefit-found-for-everolimus-plus-adjuvant-hormone-therapy-in-high-risk-early-stage-breast-cancer\/"},{"key":"cit0033","unstructured":"European Medicines Agency [Internet]. European Medicines Agency. [cited 2022 Jan 20];Available from: https:\/\/www.ema.europa.eu\/en"},{"issue":"2","key":"cit0034","first-page":"101","volume":"26","author":"Cook MM","year":"2021","journal-title":"Oncology"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01394-y"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv595"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30109-2"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.836078"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00034-6"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.011"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30817-4"},{"key":"cit0043","unstructured":"AstraZeneca. A Phase Ib\/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer [Internet]. clinicaltrials.gov; 2022 [cited 2022 Oct 6];Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04862663"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"cit0045","unstructured":"AstraZeneca. A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator\u2019s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) [Internet]. clinicaltrials.gov; 2022 [cited 2022 May 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04494425"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2009.11.041"},{"key":"cit0048","unstructured":"AstraZeneca. A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4\/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4\/6 Inhibitor in HR+\/HER2-MBC Patients with Detectable ESR1Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor+ CDK4\/6 Inhibitor- a ctDNA Guided Early Switch Study [Internet]. clinicaltrials.gov; 2022 [cited 2022 May 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04964934"},{"key":"cit0049","unstructured":"AstraZeneca. A phase III double-blind randomised study assessing the efficacy and safety of capivasertib + fulvestrant versus placebo + fulvestrant as treatment for locally advanced (inoperable) or metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+\/HER2-) breast cancer following recurrence or progression on or after treatment with an aromatase inhibitor [Internet]. clinicaltrials.gov; 2022 [cited 2022 May 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04305496"},{"key":"cit0050","unstructured":"Sharp M, Randomized DLA, Double-Blind PC, Phase 3 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-Negative (HR+\/HER2-) locally recurrent inoperable or metastatic breast cancer (KEYNOTE-B49) [Internet]. clinicaltrials.gov; 2022 [cited 2022 May 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04895358"},{"key":"cit0051","unstructured":"Roussy G, Campus C, Paris G. Phase 2, open label study of patritumab deruxtecan (U3-1402), an Anti-HER3-antibody drug conjugate (ADC), in patients with advanced breast cancer, with biomarker analyses to characterize response to therapy [Internet]. clinicaltrials.gov; 2021 [cited 2022 May 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04965766"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1279"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2214677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T12:39:20Z","timestamp":1688042360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2214677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/14656566.2023.2214677"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2214677","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}